AKEBIA THERAPEUTICS, INC. Amortization of Intangible Assets
AKEBIA THERAPEUTICS, INC. (AKBA) reported Amortization of Intangible Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-02-26
- AKEBIA THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. amortization of intangible assets for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. amortization of intangible assets for fiscal 2024 was $36.04M, a 0.00% change from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. amortization of intangible assets for fiscal 2023 was $36.04M, a 0.00% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. amortization of intangible assets for fiscal 2022 was $36.04M, a 0.00% change from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $9.01M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $9.01M derived: sum of 3 quarters · filed 2026-02-26 | $18.01M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $9.01M derived: sum of 2 quarters · filed 2026-02-26 | $18.01M derived: sum of 3 quarters · filed 2026-02-26 | $27.01M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | $9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.01M derived: sum of 2 quarters · filed 2026-02-26 | $27.01M derived: sum of 3 quarters · filed 2026-02-26 | $36.04M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $9.00M 10-Q · filed 2025-11-10 | $18.00M derived: sum of 2 quarters · filed 2025-11-10 | $27.03M 10-Q · filed 2025-11-10 | $36.02M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $9.00M 10-Q · filed 2025-08-07 | $18.02M 10-Q · filed 2025-08-07 | $27.02M derived: sum of 3 quarters · filed 2026-02-26 | $36.02M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $9.01M 10-Q · filed 2025-05-08 | $18.02M derived: sum of 2 quarters · filed 2026-02-26 | $27.02M derived: sum of 3 quarters · filed 2026-02-26 | $36.02M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.01M derived: sum of 2 quarters · filed 2026-02-26 | $27.01M derived: sum of 3 quarters · filed 2026-02-26 | $36.04M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $9.00M 10-Q · filed 2024-11-07 | $18.00M derived: sum of 2 quarters · filed 2024-11-07 | $27.03M 10-Q · filed 2024-11-07 | $36.02M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $9.00M 10-Q · filed 2024-08-08 | $18.02M 10-Q · filed 2024-08-08 | $27.02M derived: sum of 3 quarters · filed 2024-08-08 | $36.02M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $9.01M 10-Q · filed 2024-05-09 | $18.02M derived: sum of 2 quarters · filed 2024-05-09 | $27.02M derived: sum of 3 quarters · filed 2024-05-09 | $36.02M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $18.01M derived: sum of 2 quarters · filed 2024-03-14 | $27.01M derived: sum of 3 quarters · filed 2024-03-14 | $36.04M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $9.00M 10-Q · filed 2023-11-08 | $18.00M derived: sum of 2 quarters · filed 2023-11-08 | $27.03M 10-Q · filed 2023-11-08 | $36.02M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $9.00M 10-Q · filed 2023-08-28 | $18.02M 10-Q · filed 2023-08-28 | $27.02M derived: sum of 3 quarters · filed 2023-08-28 | $36.02M derived: sum of 4 quarters · filed 2023-08-28 | |
| 2022-03-31 | $9.01M 10-Q · filed 2023-05-08 | $18.02M derived: sum of 2 quarters · filed 2023-08-28 | $27.02M derived: sum of 3 quarters · filed 2023-08-28 | $36.02M derived: sum of 4 quarters · filed 2023-08-28 | |
| 2021-12-31 | $9.01M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $18.01M derived: sum of 2 quarters · filed 2023-08-28 | $27.01M derived: sum of 3 quarters · filed 2023-08-28 | $36.04M 10-K/A · filed 2023-08-28 | |
| 2021-09-30 | $9.00M 10-Q · filed 2022-11-03 | $18.00M derived: sum of 2 quarters · filed 2022-11-03 | $27.03M 10-Q · filed 2022-11-03 | $35.32M derived: sum of 4 quarters · filed 2023-08-28 | |
| 2021-06-30 | $9.00M 10-Q · filed 2022-08-04 | $18.02M 10-Q · filed 2022-08-04 | $26.32M derived: sum of 3 quarters · filed 2023-08-28 | $32.42M derived: sum of 4 quarters · filed 2023-08-28 | |
| 2021-03-31 | $9.01M 10-Q · filed 2022-05-09 | $17.32M derived: sum of 2 quarters · filed 2023-08-28 | $23.42M derived: sum of 3 quarters · filed 2023-08-28 | $32.52M derived: sum of 4 quarters · filed 2023-08-28 | |
| 2020-12-31 | $8.31M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $14.41M derived: sum of 2 quarters · filed 2023-08-28 | $23.51M derived: sum of 3 quarters · filed 2023-08-28 | $32.62M 10-K/A · filed 2023-08-28 | $31.52M 10-K · filed 2021-02-25 |
| 2020-09-30 | $6.10M 10-Q · filed 2021-11-04 | $15.20M derived: sum of 2 quarters · filed 2021-11-04 | $24.31M 10-Q · filed 2021-11-04 | $33.40M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $9.10M 10-Q · filed 2021-08-05 | $18.20M 10-Q · filed 2021-08-05 | $27.30M derived: sum of 3 quarters · filed 2022-03-01 | $36.40M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $9.10M 10-Q · filed 2021-05-10 | $18.20M derived: sum of 2 quarters · filed 2022-03-01 | $27.30M derived: sum of 3 quarters · filed 2022-03-01 | $36.40M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $18.20M derived: sum of 2 quarters · filed 2022-03-01 | $27.30M derived: sum of 3 quarters · filed 2022-03-01 | $36.40M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $9.10M 10-Q · filed 2020-11-05 | $18.20M derived: sum of 2 quarters · filed 2020-11-05 | $27.30M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $9.10M 10-Q · filed 2020-08-10 | $18.20M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $9.10M 10-Q · filed 2020-05-05 | ||||
| 2018-12-31 | $1.52M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |